Development of orally bioavailable prodrugs of fulvestrant for the treatment of metastatic/advanced breast cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e13027
Abstract: e13027 Background: Fulvestrant, a potent, selective estrogen receptor degrader, is a primary drug of choice for treating advanced metastatic hormone receptor-positive breast cancer in postmenopausal women following anti-estrogen therapy. However, the existing therapy limits to… read more here.
Keywords: bioavailability; breast cancer; prodrugs fulvestrant; development orally ... See more keywords